In what may well turn out to be a godsend for scores of people who are suffering from the potentially terminal lung cancer all over the world, it has been revealed by a recently concluded study, which was carried out by researchers from the UCSF, that a fairly straightforward gene test can prove highly effective in screening lung cancer in order to deliver goods for lung cancer patients, provided the gene test is carried out in the nick of time when the cancer is in its initial stages.

As a result of the novel development, it has been claimed by researchers that the test may well hold effectiveness in enhancing the chances of survival for patients going through the perilous lung cancer in its early stages. During the course of study, whose reports have been made available in the recent edition of the journal The Lancet, the UCSF researchers were keenly focused on determining the efficacy of a new-flanged molecular assessment in predicting results more precisely as compared to a handful of diagnostic measures being used by almost all medical professionals all over the world at present. However, the researchers claimed that for precise application of such methods the tumors are mainly expected to be belligerent and potentially harmful.

The findings of the study were based on two of the world’s largest clinical assessments ever carried out with the intent of understanding lung cancer’s molecular genetics of lung cancer and it also consisted of lung cancer patients who were in their initial stage of the ailment.

The research was supported by many medical experts from China along with researchers from the Northern California Kaiser hospitals. During the course of the study, the researchers conducted a 14-gene test that was relying on many developments made originally at UCSF but were formulated by a Mountain View firm.

The researchers successfully gauged the chances of a patient of falling prey to lung cancer over a period of around five years following their surgery for the disease, and they were successful in doing so by monitoring the biological structure of the potentially lethal tumor.

The researchers concluded by saying, “It can help enhance the chance of curing more patients, and this is not an insignificant problem”.